Slow-Release Oral Morphine Sulfate Abuse: Results of the Postmarketing Surveillance Systems for Psychoactive Prescription Drug Abuse in France

Publié le 6 mars 2013

Peyriere et al., European Addiction Research, 2013

  • Titre traduit : Abus de sulfate de morphine à libération prolongée par voie orale: Les résultats des systèmes de surveillance post-commercialisation de l’abus des médicaments psychoactifs en France
  • Auteurs : H. Peyriere, C. Eiden, J. Micallef, M. Lapeyre-Mestre, JL. Faillie, JP. Blayac et le réseau français des CEIP-Addictovigilance
  • Résumé : Few data are available concerning the diversion and abuse of morphine sulfate. In France, morphine sulfate abuse is currently investigated by the health authorities. The aim of our study was to provide data on morphine sulfate abuse in France, collected during the period 1996-2011.
    • Method: The French monitoring system for psychoactive medication abuse collected data from several sources: spontaneous reporting of cases of abuse or dependence (NotS), specific periodic surveys from specialized care centers (OPPIDUM), and community pharmacists (OSIAP).
    • Results: A total of 649 cases (75% of men, median age 34 years) were spontaneously reported: 578 cases of abuse and 71 cases of use as opiate maintenance treatment. The medication formulation was Skenan® (614 cases), and Moscontin® (35 cases). All surveys (NotS, OPPIDUM and OSIAP) showed the overrepresentation of Skenan® (from 87.9 to 94.6% of cases) that was intravenously injected in 60.4 to 61.2% of cases. Data analysis showed that patients abusing morphine sulfate have a long history of drugs abuse with history of poly-drug use.
    • Conclusion: All the data presented in this study highlight the level of morphine sulfate abuse, specify the modalities of use (intravenous route), and the risks associated with abuse (infectious diseases). This study outlines the usefulness of our epidemiological tools, and provides evidence supporting intensive surveillance.
  • Référence : Eur Addict Res 2013 Feb 15;19(5):235-244
Retour en haut